Clinical News Bristol Myers Squibb (BMS) has announced successful top-line results from its Phase III SCOUT-HCM trial. This marks the first study of a cardiac myosin inhibitor conducted specifically in adolescents aged 12 to 17 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Key Study Parameters:
-
Primary Endpoint: The trial successfully met its main objective, showing a statistically significant reduction in the Valsalva left ventricular outflow tract (LVOT) gradient at week 28 compared to the baseline.
-
Disease Context: Pediatric oHCM is a rare but severe condition characterized by cardiac hypercontractility, which is associated with substantial morbidity and long-term mortality risks.
-
Mechanism of Action: Camzyos (mavacamten) works by inhibiting excess myosin-actin cross-bridges within the sarcomere, directly addressing the underlying hypercontractility of the disease.
-
Safety Profile: The data confirmed that the drug’s safety remains consistent with its established profile in adults, with no new safety concerns emerging in the adolescent population.
-
Scale and Roadmap: The study enrolled 44 participants in a randomized, placebo-controlled setting. BMS plans to present full comprehensive results at upcoming medical congresses and engage with global health authorities regarding potential label expansion.